| | | | | | | | | | |
|
|
| Dockets Entered
On October 10, 2006
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1978N-0065
|
| Skin Bleaching Drug Products
|
|
|
| 1993N-0069
|
| Debar Mr. Shulman; Notice of Opportunity for Hearing
|
|
|
| 2004N-0234
|
| Annual Guidance Agenda
|
|
|
| 2005D-0202
|
| Guidance for Industry on Bar Code Label Requirements; Questions and Answers
|
|
|
| 2006D-0296
|
| International Conference on Harmonisation; Draft Guidance on Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria; Annex on Residue on Ignition/Sulphated Ash General Chapter;
|
|
|
|
|
|
| 2006D-0297
|
| International Conference on Harmonisation; Draft Guidance on Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria; Availability
|
|
|
| 2006D-0331
|
| Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors; Exception from Informed Consent Requirements for Emergency Research
|
|
|
| 2006D-0336
|
| Guidance for Industry and Food and Drug Administration Staff; Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions
|
|
|
| 2006D-0347
|
| Guidance for Industry, Clinical Laboratories, and FDA Staff on In Vitro Diagnostic Multivariate Index Assays
|
|
|
| 2006D-0383
|
| Characterization and Qualification of Cell Substrates and Other Biological Starting Materials Used in the Production of Viral Vaccines for the Prevention and Treatment of Infectious Diseases
|
|
|
| 2006N-0107
|
| FDA-Regulated Products Containing Nanotechnology Materials
|
|
|
| 2006P-0151
|
| Stay the current approvable letter with conditions of any and all Premarket Applications for silicone gel-filled breast implants
|
|
|
| 2006P-0361
|
| Deny Request to switch ketotifen fumarate ophthalmic solution, 0.025%
|
|
|
| 2006P-0371
|
| Immediately add a black box warning regarding the risks of tendinopathy and tendon rupture to the product labels of all fluoroquinolone antibiotics presently on the market in the United States
|
|
|
| 2006P-0390
|
| Order the Church of Scientology to clearly disclose the potential health hazards inherent in the use of the E-meter and Scientology's practice of "auditing"
|
|
|
| 2006P-0392
|
| Refrain from approving any ANDA for a Diazepam Rectal Gel that Relies on Diastat
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
| 2006P-0403
|
| Determine whether an Abbreviated New Drug Application can be filed against the listed drug Novamine 15%, manufactured by Hospira under NDA 17-957
|
|
|
| 1978N-0065
|
| Skin Bleaching Drug Products
|
|
|
| EC 6
|
| Dr. Charles Fishman
|
| Vol #:
|
| 4
|
|
|
| EC 7
|
| Dr. William Liss
|
| Vol #:
|
| 4
|
|
|
| EC 8
|
| Dr. Jo Bohannon
|
| Vol #:
|
| 4
|
|
|
| 1993N-0069
|
| Debar Mr. Shulman; Notice of Opportunity for Hearing
|
|
|
| LET 4
|
| FDA/DDM to Robert Shulman
|
| Vol #:
|
| 1
|
|
|
| 2004N-0234
|
| Annual Guidance Agenda
|
|
|
| EC 5
|
| Rammell Consulting
|
| Vol #:
|
| 1
|
|
|
| 2005D-0202
|
| Guidance for Industry on Bar Code Label Requirements; Questions and Answers
|
|
|
| GDL 3
|
| Guideline
|
| Vol #:
|
| 1
|
|
|
| NAD 3
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2006D-0296
|
| International Conference on Harmonisation; Draft Guidance on Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria; Annex on Residue on Ignition/Sulphated Ash General Chapter;
|
|
|
|
|
|
| C 1
|
| Wyeth Pharmaceuticals, Inc.
|
| Vol #:
|
| 1
|
|
| | | | | | | | |
|
|
| 2006D-0297
|
| International Conference on Harmonisation; Draft Guidance on Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria; Availability
|
|
|
| C 2
|
| Parenteral Drug Association (PDA)
|
| Vol #:
|
| 1
|
|
|
| EC 3
|
| Amgen
|
| Vol #:
|
| 1
|
|
|
| 2006D-0331
|
| Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors; Exception from Informed Consent Requirements for Emergency Research
|
|
|
| EC 36
|
| Mr. Warren Dowler
|
| Vol #:
|
| 2
|
|
|
| 2006D-0336
|
| Guidance for Industry and Food and Drug Administration Staff; Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions
|
|
|
| EC 3
|
| Genetic Alliance
|
| Vol #:
|
| 1
|
|
|
| 2006D-0347
|
| Guidance for Industry, Clinical Laboratories, and FDA Staff on In Vitro Diagnostic Multivariate Index Assays
|
|
|
| EC 4
|
| Genetic Alliance
|
| Vol #:
|
| 1
|
|
|
| 2006D-0383
|
| Characterization and Qualification of Cell Substrates and Other Biological Starting Materials Used in the Production of Viral Vaccines for the Prevention and Treatment of Infectious Diseases
|
|
|
|
|
|
| EC 1
|
| Mrs. Maria Rugg
|
| Vol #:
|
| 1
|
|
|
| 2006N-0107
|
| FDA-Regulated Products Containing Nanotechnology Materials
|
|
|
| EC 16
|
| Consumers Union
|
| Vol #:
|
| 12
|
|
|
| 2006P-0151
|
| Stay the current approvable letter with conditions of any and all Premarket Applications for silicone gel-filled breast implants
|
|
|
| EC 747
|
| Mrs. Mary Lahan
|
| Vol #:
|
| 3
|
|
|
| EC 748
|
| National Organization for Women
|
| Vol #:
|
| 3
|
|
|
| EC 749
|
| n/a
|
| Vol #:
|
| 3
|
|
|
| EC 750
|
| African American Women in Touch
|
| Vol #:
|
| 3
|
|
|
| EC 751
|
| Breast Cancer Action
|
| Vol #:
|
| 3
|
|
|
| EC 752
|
| Mrs. Susan Boone
|
| Vol #:
|
| 3
|
|
|
| EC 753
|
| Ms. Gail Hamilton
|
| Vol #:
|
| 3
|
|
|
| EC 754
|
| Ms. Leslie Fladung
|
| Vol #:
|
| 3
|
|
|
| EC 755
|
| Humantics Foundation for Women
|
| Vol #:
|
| 3
|
|
|
| EC 756
|
| Mrs. Eileen Bento
|
| Vol #:
|
| 3
|
|
|
| EC 757
|
| Mrs. Cosima Meyer
|
| Vol #:
|
| 3
|
|
|
| EC 758
|
| Mrs. Susan Ayers
|
| Vol #:
|
| 3
|
|
|
| EC 759
|
| Miss. Jessica Maddox
|
| Vol #:
|
| 3
|
|
|
| EC 760
|
| Mrs. Rebecca Smith-Miles
|
| Vol #:
|
| 3
|
|
|
| EC 761
|
| Mrs. Cindy Fuchs-Morrissey
|
| Vol #:
|
| 3
|
|
|
| EC 762
|
| Command Trust
|
| Vol #:
|
| 3
|
|
|
| EC 763
|
| In the Know
|
| Vol #:
|
| 3
|
|
|
| EC 764
|
| Mrs. Rosalynn Maudlin
|
| Vol #:
|
| 3
|
|